Key result
Prevalent heart failure significantly increased the risk of overanticoagulation (INR ≥ 6.0) in patients on coumarins (Risk 1.66; 95% CI 1.33-2.07), with incidental cases showing a similar risk.
Why the study?
Does heart failure increase the risk of overanticoagulation (INR ≥ 6.0) in patients treated with coumarin anticoagulants?
Cohort (n=1,077)
No
Does heart failure increase the risk of overanticoagulation (INR ≥ 6.0) in patients treated with coumarin anticoagulants?
Effect estimate: Risk 1.66 (95% CI 1.33-2.07)
Heart failure independently increases the risk of overanticoagulation in patients on coumarins, highlighting the need for closer INR monitoring in this population.
No takes yet. Share an insight, caveat, or question.
Supports closer INR monitoring in HF patients on coumarins; leaves open prospective validation of benefit.
Visser et al. (2004) conducted a cohort in Heart failure on coumarin anticoagulants (n=1,077). Heart failure (exposure) vs. No heart failure was evaluated on First occurrence of an international normalized ratio (INR) ≥ 6.0 (Risk 1.66, 95% CI 1.33-2.07). Prevalent heart failure significantly increased the risk of overanticoagulation (INR ≥ 6.0) in patients on coumarins (Risk 1.66; 95% CI 1.33-2.07), with incidental cases showing a similar risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: